E-Cigarettes and Vaping
From September 2018, Retrieve Those FiltersE-cigarettes and vaping are everywhere these days, and they’re becoming more and more popular with adolescents and teenagers. Are they safe? What are the risks of electronic cigarettes? And have they been shown to help people quit smoking traditional cigarettes? In this segment, Brandon Grove walks …
10min 15Brandon Grove, MD
Spider Bites
From November 2017, Lytes and BitesSpider bites of clinical consequence are rare. In North America there are only a few spiders whose bites cause clinically relevant pathology requiring medical treatment beyond basic wound care. These species and the clinical picture resulting from their bites are reviewed in this segment. •
15min 9Mizuho Morrison, DO and Matthieu DeClerck, MD
Ondansetron: Autobot or Decepticon?
From June 2017, Legions of LesionsDr. Smith reviews the latest studies and guidelines concerning ondansetron in the treatment of hyperemsis gravidarum. Given potential, though unlikely, concerns about congenital cardiac malformations and maternal QT prolongation, it should be considered as a second line option, but definitely an …
13min 54Clay Smith, MD and Mizuho Morrison, DO
Paper Chase 4: "Zombie" Outbreak due to the Synthetic Cannabinoid AMB-FUBINAC
From April 2017, Antibiotics in the Lyme-LightSynthetic cannabinoid, AMB-FUBINACA, use is associated with Zombie-like presentation, right down to the groaning and slow limb movement
4min 11Andrew Buelt, DO and Joe Weatherly, DO
Mental Health Effects of Marijuana
From February 2017, Sweat Puddled, Brains MuddledMarijuana use is an emerging area of research in mental health. It has been linked to increased risk of psychosis in vulnerable individuals, paranoia, amotivation syndrome, and IQ loss. Many patients use it to self-treat anxiety and depression symptoms. Currently, there is not enough evidence to …
11min 33Rob Orman, MD and Shawn Hersevoort, MD, MPH
The Primary Care RAP Hot Sheet: December 2016
From December 2016, The Primary Care RAP Hot Sheet: December 2016Andrew and Heidi talk about medical marijuana legislation, new statin guidelines, and the diabetes drug that has everyone talking.
5min 55Andrew Buelt, DO and Heidi James, MD
Exercise Induced Hyponatremia
From December 2016, Ear Pain is but a MemoryWhen is hyponatremia not treated like the usual hyponatremia you see in Grandma from the nursing home? When it is in a patient running 50 miles and drinking a LOT of water, that is when! •
26min 3John Anderson, MD and Rob Orman, MD
Opiate Detox
From September 2016, Best Weight, Best Exercise!Discuss strategies for managing opiate detoxification and acute withdrawal symptoms.
16min 10Ken Starr, MD and Rob Orman, MD
Lead Poisoning
From September 2016, Best Weight, Best Exercise!From the Festival of Saturn in ancient Rome to the water supply in Flint, Michigan, lead toxicity has been a scourge of humanity for millennia. •
18min 9Stuart Swadron, MD FAAEM, Sean Nordt, MD PharmD FAAEM, and Rob Orman, MD
Paper Chase 2: Prescribe Sex Over Medications for Renal Stone Expulsion
From May 2016, The Sexology of Radicular Back PainMore evidence suggesting that medical expulsive therapy might not work.
6min 29Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 4: Oral Fluconazole in Pregnancy? Still a Conundrum.
From May 2016, The Sexology of Radicular Back PainThink twice before prescribing oral fluconazole in pregnancy.
4min 18Andrew Buelt, DO and Joe Weatherly, DO
Things I Do But Should I? Pregabalin in Radicular Back Pain
From May 2016, The Sexology of Radicular Back PainPregabalin is a commonly used medication in back pain. Should it be?
9min 1Adrien Selim, MD and Vanessa Cardy, MD
Paper Chase 5: Prenatal SSRI's and Increased Risk of Autism, Developmental Delay
From April 2016, Hernias and OvariesDiscuss the recent article by Harrington, Rebecca A., et al. "Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay." Pediatrics 133.5 (2014): e1241-e1248. •
5min 53Andrew Buelt, DO and Joe Weatherly, DO
Pharmacology Rounds: Death from NSAIDS
From March 2016, Where Has All The Testosterone Gone?Any medication we prescribe or recommended is essentially a selective poison, and NSAIDS are no exception. Current data suggests that most NSAIDS increase vascular risk (especially coronary events) with a number needed to harm of 3 in 1000. •
7min 19Rob Orman, MD and Bryan Hayes, PharmD
Pharmacy Rounds: Tramadol
From March 2016, Where Has All The Testosterone Gone?Bryan Hayes weighs in on why he never invites tramadol to dinner parties.
8min 37Rob Orman, MD and Bryan Hayes, PharmD
Pharmacy Rounds: Antidepressants + NSAIDs = Bad?
From March 2016, Where Has All The Testosterone Gone?Should we avoid prescribing NSAIDS to our patients taking antidepressants?
6min 40Rob Orman, MD and Bryan Hayes, PharmD
Things I Do, But Should I? Celecoxib
From February 2016, The Allergy That Isn't and the B-12 That IsAre COX-2 inhibitors a good NSAID choice for elderly patients with pain issues? Sometimes yes and sometimes no. In a new recurring segment, Vanessa Cardy and Adrian Selim explore GI, renal, and cardiovascular risks of selective and nonselective NSAIDs. •
10min 3Adrien Selim, MD and Vanessa Cardy, MD
Paper Chase 4: Anticoagulant Treatment for Unprovoked Pulmonary Embolism
From February 2016, The Allergy That Isn't and the B-12 That IsAmong patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo. •
5min 41Andrew Buelt, DO and Joe Weatherly, DO
Introduction: Functional Dyspepsia
From February 2016, The Allergy That Isn't and the B-12 That IsHave you ever gone a week in clinic without seeing a patient with dyspepsia? Some have true structural disease like peptic ulcers or even cancer. Most, however, will end up with no discernible cause of their symptoms and end up with the diagnosis of ‘functional dyspepsia’. In this segment, we …
12min 51Rob Orman, MD and Andrew Buelt, DO
Paper Chase 1: Empagliflozin and Mortality in Type 2 Diabetic Patients
From January 2016, Palliative Cerumen EmergenciesPatients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. •
7min 15Andrew Buelt, DO and Joe Weatherly, DO
‹ PreviousNext ›